TRIAL DETAIL

A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients

Drug:
Trial Name:
A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients
NCT#:
Conditions:
Gastrointestinal Stromal Tumor
Status:
Completed
Phase:
1
Start Date 02/01/2013
Age of Trial (yrs) 9.4
Treatment Phase:
Gleevec-resistant
Drug Category:
KIT/PDGFRA inhibitor + PI3K inhibitor
Strategy:
Block KIT + Block KIT Signal Path
Trial Type:
Specifically GIST and only GIST
Other Protocol IDs:
CSTI571X2103, 2012-003273-25
Sponsor:
Novartis
Patient Contact:
Novartis Pharmaceuticals 1-888-669-6682
Contact email:
Contact Phone:
Randomized:
IV or Oral:
Oral
Trial Notes:
A Dose-finding Phase Ib Multicenter Study of Imatinib in Combination With the Oral Phosphatidyl-inositol 3-kinase (PI3K) Inhibitor BYL719 in Patients With Gastrointestinal Stromal Tumor (GIST) Who Failed Prior Therapy With Imatinib and Sunitinib

Trial Links

Trial Results

 

Drug Information

Trial Sites

Name
Address
City
State
Zip
Country
Leuven
B-3000
Belgium
119-129
Barcelona
08035
Spain
1475 Northwest 12th Ave
Miami
FL
33136
USA
Lebanon
NH
03756
USA
Portland
OR
97239
USA
Bordeaux
33076
France
Lyon
69373
France
Essen
Germany
Bologna
40138
Italy
Seoul
138-736
Republic of Korea
Candiolo
TO
10060
Italy
Groningen
9713 GZ
Netherlands
Leeds
LS9 7TF
UK
Lindenberger Weg 80
Berlin
D-13125
Germany
via Giacomo
Milan
20133
Italy
Leiden
2300 RC
Netherlands
550 Wilmslow Rd
Manchester
Lancashire
M20 4BX
UK